Abbott Laboratories (ABT) Cash from Financing Activities (2009 - 2026)

Abbott Laboratories has disclosed Cash from Financing Activities across 18 years of filings, most recently posting -$3.5 billion for Q2 2026.

• In Q2 2026, Cash from Financing Activities fell 220.69% year-over-year to -$3.5 billion; the TTM figure through Jun 2026 stood at $10.6 billion (up 261.45% YoY), while the FY2025 annual figure was -$6.3 billion, down 16.75% from the prior year.
• Cash from Financing Activities came in at -$3.5 billion for Q2 2026 at Abbott Laboratories, down from $17.3 billion in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $17.3 billion in Q1 2026 to a low of -$3.8 billion in Q1 2022.
• Average Cash from Financing Activities over 5 years is -$702.5 million, with a median of -$1.5 billion recorded in 2022.
• Year-over-year, Cash from Financing Activities slumped 295.35% in 2022 and jumped 942.48% in 2026.
• Over 5 years, Cash from Financing Activities stood at -$1.5 billion in 2022, then sank by 40.84% to -$2.1 billion in 2023, then grew by 9.31% to -$1.9 billion in 2024, then climbed by 24.93% to -$1.4 billion in 2025, then tumbled by 151.83% to -$3.5 billion in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$3.5 billion in Q2 2026, $17.3 billion in Q1 2026, and -$1.4 billion in Q4 2025.